We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FTC Told Impax Can't Justify Opana Reverse Payment

Law360 (September 14, 2018, 5:15 PM EDT) -- Federal Trade Commission attorneys looking to revive a pay-for-delay case over the opioid pain medication Opana ER told the commission that the central issue in the appeal is that generics maker Impax can't tie the payment it received from Endo Pharmaceuticals Inc. to its broader settlement agreement.

FTC staff filed their reply brief Wednesday in the appeal of Administrative Law Judge D. Michael Chappell's May dismissal of the case, which alleges Impax Laboratories Inc. accepted an illegal reverse payment in exchange for delaying the entry of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.